(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 August 2021 (26.08.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/165429 A1

(51) International Patent Classification:
A61K 31/18 (2006.01) *A61K 45/06* (2006.01)
A61K 31/00 (2006.01) *A61P 11/06* (2006.01)
A61K 31/573 (2006.01)

(21) International Application Number:
PCT/EP2021/054078

(22) International Filing Date:
18 February 2021 (18.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20158749.0 21 February 2020 (21.02.2020) EP

(71) Applicant: **DOMPE' FARMACEUTICI SPA** [IT/IT]; VIA SANTA LUCIA 6, 20121 MILANO (IT).

(72) Inventors: **RUSSO, Remo De Castro**; c/o Instituto de Ciencias Biological - ICB, UFMG, Av. Antonio Carlos, 6627 Pampulha (BR). **TEIXEIRA, Mauro Martin**; c/o Instituto de Clencias Biologicas - ICB, UFMG, Departamento de Bioquimica e Imunologia, Av. Antonio Carlos, 6627 Pampulha (BR). **ALLEGRETTI, Marcello**; C/0 DOMPE' FARMACEUTICI SPA, Via Campo di Pile, snc, 67100 L'Aquila (IT). **BRANDOLINI, Laura**; c/o Dompé farmaceutici spa, Via Campo di Pile, 67100 L'Aquila (IT).

(74) Agent: **MAURI, Elisabetta Maria Ester**; C/0 DOMPE' FARMACEUTICI SPA, VIA SANTA LUCIA 6, 20121 MILANO (IT).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

(57) Abstract: The present invention relates to a combination of a CXCL8 activity inhibitor and a corticosteroid, and a pharmaceutical composition thereof, for use in the treatment of corticosteroid-insensitive asthma as well as to a method for treating corticosteroid-insensitive asthma by administration of said pharmaceutical composition.

WO 2021/165429 A1